CrystalGenomics Inc (083790) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
40
About the Report
About the Report
Summary
CrystalGenomics Inc (CrystalGenomics) is a biopharmaceutical company that discovers and develops drugs structural chemoproteiomics-based drugs. The company's pipeline product candidate includes CG100649, a tissue specific anti-inflammatory agent with osteoarthritis, cardiovascular, gastrointestinal, and renal safety profiles. Its drug candidates also comprise CG200745, a histone deacetylase inhibitor that is developed as an anticancer agent for various solid tumors; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus. CrystalGenomics offers protein, assay and structure services. The company's technologies include soluble protein solution, structural chemo proteomics, and structural-based drug factory. It partners with pharmaceutical and venture capital groups. CrystalGenomics is headquartered in Seongnam, South Korea.
CrystalGenomics Inc (083790)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
CrystalGenomics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CrystalGenomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
CBT Pharma Enters into Agreement with CrystalGenomics 11
CrystalGenomics Enters into Distribution Agreement with Daewoong Pharma 12
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 13
CrystalGenomics Enters into Co-Marketing Agreement with Daewoong Pharma 14
SAFC Pharma Enters Into Co-Development Agreement With CrystalGenomics 15
Licensing Agreements 16
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 16
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
TR-Pharm Enters into Licensing Agreement with CrystalGenomics 18
Equity Offering 19
CrystalGenomics to Raise USD0.8 Million in Private Placement of Shares 19
CrystalGenomics Raises USD12.7 Million in Private Placement of Shares 20
CrystalGenomics Completes Private Placement Of Shares For USD 2.6 Million 21
Acquisition 22
CrystalGenomics Acquires Hwail Pharma 22
CrystalGenomics Inc-Key Competitors 23
CrystalGenomics Inc-Key Employees 24
CrystalGenomics Inc-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Product News 26
04/19/2017: Aptose Biosciences To Present CG-806 Data At AACR Hematologic Malignancies Meeting 26
01/23/2017: Aptose Prioritizes Development of CG'806 First-in Class FLT3/BTK Inhibitor 27
Product Approvals 28
Dec 26, 2017: FDA Grants Orphan Drug Designation to Aptose Biosciences for CG'806 in Acute Myeloid Leukemia 28
Clinical Trials 29
Jun 15, 2018: Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association 29
May 17, 2018: Aptose to Present New CG'806 Data at the 23rd Congress of the European Hematology Association 30
Apr 16, 2018: Aptose Presents New Preclinical Data on CG'806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting 31
Apr 16, 2018: OHSU and Aptose Present New CG806 Preclinical Data at 2018 AACR Annual Meeting 32
Mar 15, 2018: Aptose to Present Preclinical Data of CG'806 at the 2018 AACR Annual Meeting 33
Dec 11, 2017: Aptose Presents New Preclinical Data on CG'806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting 34
Dec 11, 2017: OHSU and Aptose Present CG'806 Preclinical Data at ASH 59th Annual Meeting 35
Nov 01, 2017: Aptose to Present New CG'806 Data at the 2017 ASH Annual Meeting 36
Sep 12, 2017: Aptose Biosicences and CrystalGenomics Announce Issuance of U.S. Patent for CG'806 37
May 08, 2017: OHSU and Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting 38
May 08, 2017: Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented at AACR Hematologic Malignancies Meeting 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Figure
List of Figures
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CrystalGenomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CrystalGenomics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CrystalGenomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CBT Pharma Enters into Agreement with CrystalGenomics 11
CrystalGenomics Enters into Distribution Agreement with Daewoong Pharma 12
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 13
CrystalGenomics Enters into Co-Marketing Agreement with Daewoong Pharma 14
SAFC Pharma Enters Into Co-Development Agreement With CrystalGenomics 15
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 16
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
TR-Pharm Enters into Licensing Agreement with CrystalGenomics 18
CrystalGenomics to Raise USD0.8 Million in Private Placement of Shares 19
CrystalGenomics Raises USD12.7 Million in Private Placement of Shares 20
CrystalGenomics Completes Private Placement Of Shares For USD 2.6 Million 21
CrystalGenomics Acquires Hwail Pharma 22
CrystalGenomics Inc, Key Competitors 23
CrystalGenomics Inc, Key Employees 24
CrystalGenomics Inc, Subsidiaries 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.